A study testing whether a new weekly shot from Lilly, retatrutide, can help with weight.
What this means for you
- Who can join
- Adults 18+, have obesity, BMI 27+.
- What you take
- retatrutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 2.8 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Obesity. Also studied in: Overweight.
Full scientific study title: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight.
Who can join
Adults 18+, have obesity, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have a Body Mass Index (BMI) at screening
- >= 30 kilogram per square meter (kg/m2) OR
- >= 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
- Have at least one unsuccessful attempt to lose weight by dieting
Key exclusion criteria
- Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening
- Have a prior or planned surgical treatment for obesity
- Have type 1 diabetes or type 2 diabetes
- Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- Have had within the past 90 days before screening:
Where this study is enrolling
This trial has 20 sites across 14 states. Contact a site coordinator directly to start screening.
Arizona1 site
- Arizona Research CenterPhoenix, Arizona602-863-6363
California2 sites
- Care Access - Huntington BeachHuntington Beach, California714-378-2440
- Los Angeles Institute for Metabolic ResearchLos Angeles, California213-373-8380
Florida2 sites
- New Horizon Research CenterMiami, Florida
- Encore Medical Research - WestonWeston, Florida
Hawaii1 site
- Pacific Diabetes & Endocrine CenterHonolulu, Hawaii808-526-0303
Kentucky1 site
- Monroe Biomedical Research - LouisvilleLouisville, Kentucky
Massachusetts1 site
- Brigham and Women's Hospital Diabetes ProgramBoston, Massachusetts617-278-0454
Michigan1 site
- Great Lakes Research Group, Inc.Bay City, Michigan
New York2 sites
- NYC Research INCLong Island City, New York
- Weill Cornell Medical CollegeNew York, New York
North Carolina1 site
- Care Access - RaleighRaleigh, North Carolina877-791-0656
Tennessee1 site
- New Phase Research and DevelopmentKnoxville, Tennessee
Texas4 sites
- Velocity Clinical Research, DallasDallas, Texas
- Cedar Health Research - Texas Native HealthDallas, Texas214-253-8170
- Cedar Health ResearchDallas, Texas
- Cedar Health Research - Fort WorthFort Worth, Texas
Utah1 site
- Advanced Research InstituteOgden, Utah801-409-2040
Virginia1 site
- Dominion Medical Associates, Inc.Richmond, Virginia804-249-2111
West Virginia1 site
- CAMC Institute for Academic MedicineCharleston, West Virginia
Timeline
Started enrolling: 2026-01-24. Expected completion: 2028-11. Last updated on ClinicalTrials.gov: 2026-05-22.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
